Date published: 
23 May 2021
Intended audience: 
General public

The joint statement provides updated information about TTS and reaffirms ATAGI’s previous advice regarding the safe use of the AstraZeneca COVID-19 Vaccine.

It provides greater clarity on the nature of TTS and narrows the conditions determined to be contraindications for use of the vaccine.

The Chief Medical Officer (CMO) has also written to healthcare professionals regarding the joint statement.

Read the statement